CT and PET: Early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor

American Journal of Roentgenology

Volumn 189, Issue 6, 2007, Pages 1450-

  Holdsworth, Clay H ^a,b   Badawi, Ramsey D ^c   Manola, Judith B ^b   Kijewski, Marie F ^d   Israel, David A ^b,d   Demetri, George D ^b   Van Den Abbeele, Annick D ^b,d  

^a Massachusetts College of Pharmacy and Health Sciences   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CT; Gastrointestinal stromal tumor; Imatinib mesylate; Oncologic imaging; PET

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; METHODOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; PILOT PROJECTS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PYRIMIDINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES;

EID: 36448965201     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2496     Document Type: Article

References (0)